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LAY ABSTRACT
People who have a stroke may suffer from complica-
tions such as spasticity (stiffness in muscles due to 
muscle contraction). Spasticity can cause difficulty 
with day-to-day activities and may also cause pain. 
People with stroke may have spasticity without it being 
diagnosed, and people who need treatment may not 
be seen by healthcare professionals. Through formal 
consultation and analysis with expert doctors, phy-
siotherapists and occupational therapists a range of 
simple and practical recommendations to help impro-
ve treatment is proposed. An acronym ‘ACTION’ was 
developed, referring to limitation of Activity, difficulty 
with Care tasks, Tight muscles, Integrity of the skin, 
Ongoing pain and Nails digging in (to the palm of the 
hand). The acronym was designed to help clinicians 
identify spasticity following a stroke that might cause 
problems. The recommendations from the expert gro-
up are focused on clinical practice in the UK but are 
applicable to other countries and healthcare systems. 
Objective: To identify barriers to appropriate refer-
ral and treatment for patients with spasticity and 
present solutions that address these in a pragmatic 
way. 
Methods: Using the findings of interviews conduc-
ted with UK healthcare professionals on the mana-
gement of post-stroke spasticity, a consensus mee-
ting was held involving 7 UK spasticity experts. The 
panel identified barriers to timely identification and 
referral of patients in the acute and post-acute care 
settings. Barriers were prioritized using a consen-
sus framework based on impact and resolvability 
and a series of final recommendations were agreed. 
Results: High-priority barriers broadly related to: 
insufficient awareness of spasticity symptoms and 
benefits of treatment, limited access to spasticity 
services and lack of standardized pathways for 
post-stroke spasticity identification. Potential solu-
tions included the appointment of an experienced 
member of the acute team to gain expertise in 
spasticity identification, patient education of spas-
ticity symptoms and a greater utilization of training 
resources for healthcare professionals. 
Conclusion: To address the barriers identified, we 
provide a series of consensus recommendations. As 
a key recommendation, we propose a set of indica-
tors for the identification of stroke patients requi-
ring specialist assessment and the use of the asso-
ciated acronym “ACTION”. 
Key words: stroke; post-stroke spasticity; rehabilitation; 
health services; patient; physiotherapy.
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Spasticity is a common feature of many neurological disorders, such as stroke. It is part of the upper motor 
neurone syndrome and it manifests as increased muscle 
tone associated with spasms and/or clonus (1). First 
described as “a velocity-dependent resistance to passive 
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movement with exaggerated tendon jerks resulting from 
hyperexcitability of the stretch reflexes” (2), it has more 
recently been defined as “disordered sensorimotor control, 
resulting from an upper motor neurone lesion, presenting 
as intermittent or sustained involuntary activation of 
muscles” (3), which more accurately reflects the clinical 
presentation and is the definition used in this paper. 
Epidemiological studies have shown that up to 38% 
of stroke patients are affected by spasticity (4), which 
equates to more than 40,000 newly affected patients with 
post-stroke spasticity (PSS) per year in England alone (5). 
Onset of spasticity can occur at any time after stroke (6). 
The estimated prevalence of PSS is 21% in the first week 
(7), 19% at 3 months, 22% at 4 months, 43% at 6 months 
(8) and 17–46% at 12 months post-stroke (9–11).  Senso-
rimotor function has been found to be the most important 
predictor for any, or severe, spasticity (12).  Spasticity 
could be predicted with 85% sensitivity and 90% speci-
ficity 10 days post stroke using a prediction model (12).
Spasticity has a negative impact on post-stroke phy-
sical and mental wellbeing, as it contributes to functional 
limitations, including difficulties with personal hygiene 
and mobility, with subsequent implications for societal 
participation and quality of life. As a result, patients can 
experience depression, anxiety and poor self-esteem 
(13, 14), while their caregivers may also be affected by 
depression and anxiety due to the considerable burden of 
care placed upon them (15). 
Patients with spasticity are at risk of developing 
secondary complications, including contractures and 
pressure sores (16). Complications can emerge as early 
as 4 weeks post-stroke (13), so it is essential that spasti-
city is recognized early and an appropriate management 
plan put in place. Early intervention may help to prevent 
complications that impede patient rehabilitation and may 
facilitate more functional outcomes in some individuals 
(13). Effective spasticity management requires a multi-
disciplinary approach that combines physical rehabilita-
tion (including postural management) with, if necessary, 
pharmacological interventions (16). 
Recent analyses have revealed significant under-
recording of PSS in primary care data, reflecting likely 
under-diagnosis or under-reporting of the condition (17).
Notably, in contrast to other common post-stroke com-
plications, the UK Sentinel Stroke National Audit Pro-
gramme (SSNAP) does not specifically monitor spasticity 
at any point in the stroke patient journey. Furthermore, 
there is no nationally agreed pathway for PSS, and a ge-
neral lack of formalized protocols for the identification, 
monitoring and referral of patients with PSS or at high 
risk of developing the condition. As a result, patients 
with PSS are often only referred for spasticity treatment 
once secondary complications have arisen. Moreover, an 
unknown number of patients with problematic spasticity 
may receive no treatment at all, because their spasticity 
has not been identified. 
In view of these challenges, an expert consensus panel 
was convened to: (i) assess the barriers to timely identifi-
cation and referral of patients; and (ii) identify potential 
solutions to optimize management of PSS.
METHODS
A consensus meeting was held involving a multidisciplinary 
panel comprising 7 UK expert spasticity practitioners, drawn 
from acute stroke, secondary and tertiary rehabilitation, in-
termediate and community care (2 consultant neurologists, 2 
consultant physiotherapists, 1 consultant in stroke medicine, 
geriatrics and general medicine, 1 consultant in rehabilitation 
medicine, 1 advanced occupational therapist). The aim of the 
meeting was to discuss barriers to the identification and referral 
of patients with PSS and propose solutions to overcome them. 
The panel used findings gathered from in-depth 1-h telephone 
qualitative interviews with 12 healthcare professionals (HCPs) 
(from across the UK) selected based on their knowledge, skills 
and working in the field of spasticity. Structured interviews were 
carried out to gain insights into PSS referral and management 
practices in the UK and were conducted by 2 interviewers from 
a medical communications agency. Ten of the interviewees were 
based in acute care or hospital-based rehabilitation settings (2 
consultant physiotherapists, 6 consultants in rehabilitation medi-
cine, 1 consultant in neuro-rehabilitation and 1 consultant in 
geriatrics and stroke medicine), while 2 were based in the com-
munity rehabilitation setting (2 community physiotherapists). 
One of the interviewees was subsequently invited to become a 
member of the consensus panel. All interviewees were asked a 
set of questions based on the following topics: sources of patient 
referral, screening and assessment of patients, treatment goals, 
factors influencing referral and barriers to timely referral and 
treatment. Thematic analysis was undertaken by the interviewers 
and a report documenting the interview themes was compiled. 
The consensus meeting was conducted as follows: (i) A round-
table discussion was held based on the interview outcomes. (ii) 
The consensus panel was split into 2 breakout groups, focusing 
on acute and post-acute care. (iii) The 2 groups discussed and 
proposed barriers that hinder the timely identification and 
referral of patients with PSS in their setting. (iv) Each group 
prioritized the identified barriers diagrammatically based on 
impact and resolvability using implementation matrices. (v) The 
groups reconvened to present, discuss and refine the identified 
barriers. (vi) The panel split again into “acute” and “post-acute 
care” breakout groups to identify practical, implementable 
solutions to address those barriers deemed likely to have the 
greatest impact on patients and to be surmountable in the short 
term. (vii) The 2 groups reconvened and presented the proposed 
solutions to the full panel and the final recommendations to 
overcome the prioritized barriers were discussed. 
All breakout and panel discussion sessions were facilitated by 
external moderators. Proceedings were audio recorded and the 
outcomes following the consensus meeting were consolidated 
into a draft paper.
RESULTS
In-depth interviews with UK healthcare professionals
Key findings from in-depth telephone interviews with 12 
UK HCPs involved in spasticity management are summa-
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Table I. Summary of findings from in-depth interviews with UK healthcare professionals
Topic areas Themes from interviews
Sources of patient referral • Physiotherapists in acute care or the community are most likely to refer patients with PSS for treatment, whereas GPs 
rarely refer unless advised by a therapist 
• Some spasticity centres do not accept direct referrals from physiotherapists; they must come via a GP
• Seven interviewees felt that some groups of patients might be less likely to receive a referral for specialist treatment than 
others, for example, elderly patients in nursing homes who may have cognitive difficulties, patients with communication 
difficulties, and frail patients who may have difficulty complying with physical therapy
Screening and assessment of patients • 8 out of 12 interviewees said that stroke patients are routinely assessed for spasticity while in acute care
• Assessment for spasticity on the acute ward is primarily carried out by physiotherapists
• Patients are rarely identified as being at risk of spasticity prior to spasticity onset 
Treatment goals • Treatment goals for spasticity are mainly passive (though active treatment goals are relevant in some cases) and include 
improved hygiene, improved/maintained range of movement and preservation of skin integrity
Barriers to timely identification and 
treatment of patients with PSS 
Level of awareness 
• There is often insufficient awareness among HCPs outside the field of rehabilitation on the signs of spasticity, benefits 
of treatment and specialist spasticity services available 
• Patients and their carers need to be educated about spasticity, the factors that can worsen the condition and the services 
and treatments that are available to help manage it
• High staff turnover in nursing homes can hinder measures to improve awareness of the signs of spasticity and benefits 
of early treatment
• Uncertainty among some HCPs regarding the effectiveness of some interventions may reduce the likelihood of referral
Lack of capacity 
• Capacity of specialist spasticity services varies greatly across the UK and lack of service capacity results in delays after 
referral
• Services are better developed in areas serving a larger population and with consequently larger numbers of patients 
more likely to be referred
• In some areas, individual services are not always well linked and communication between them is often limited reducing 
flexibility in service provision
• Nationally the number of stroke patients is increasing, which puts increased pressure on existing spasticity services
Other barriers
• Emphasis on early discharge in the acute stroke setting means that most patients with PSS are referred after inpatient 
discharge and managed as outpatients, resulting in treatment delays
• Routine follow-up of stroke patients beyond the typical 6-week follow-up appointment is often limited. This reduces the 
opportunities for spasticity detection and referral
• Spasticity treatment is a small (but important) component of overall patient care and is not therefore identified as a primary 
focus for commissioning. In some cases, this means, individual funding requests are required for treatment with BoNT-A
BoNT-A: botulinum toxin A; GP: general practitioner; PSS: post-stroke spasticity.
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rized in Table I. Barriers to timely patient identification 
and referral identified during the interviews included: 
lack of awareness on the signs of spasticity and benefits 
of treatment among HCPs, patients and carers; limited 
capacity of services; inaccessibility or absence of servi-
ces; and lack of adequate patient follow-up. 
Fig. 1. Key barriers identified and prioritized during the consensus meeting and their positions within the patient journey.
Specialist rehabilitation  
services / spasticity services 
Re-entry for prior rehabilitation patients  
via self-referral (in some centres) or GP
DISCHARGE
EARLY SUPPORTED DISCHARGE
6-month stroke follow-up
 (minority of centres)
Patient in the community
Community services  
(usually for 12 weeks)
Acute care / stroke unit
HIGH PRIORITY BARRIERS
•  Limited time window for identification of PSS  
due to short stay in acute care
•  Lack of standardized process for assessment  
of spasticity
• Inconsistent training on spasticity among acute staff 
HIGH PRIORITY BARRIERS
•  Poor knowledge about spasticity signs and benefits  
of treatment among HCPs in the community
•  Lack of standardized process for assessment of spasticity
•  Limited access to specialist spasticity services and  
expertise in the community
•  Lack of patient / carer education on spasticity signs  
and access to services
Re-entry via  
self-referral  
or GP
Inpatient or outpatient
BARRIERS
BARRIERS
BARRIERS
BARRIERS
HIGH PRIORITY BARRIERS
•  Lack of patient / carer education on  
spasticity signs and access to services
HIGH PRIORITY BARRIERS
•  Lack of standardized process  
for assessment of spasticity
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Table II. Barriers and solutions proposed during the consensus meeting
Barriers Potential solutions to high priority* barriers 
Barriers identified by acute care breakout group Potential solutions identified by acute care breakout group
High priority* • Limited time window: time for identification and referral is limited 
by the short duration of stay in acute care
• Lack of a standardized stroke protocol specific for identification of 
PSS 
• Several unvalidated spasticity measurement tools exist, but 
none are included in standardized stroke management protocols. 
Moreover, a gold-standard tool in assessing spasticity is currently 
lacking  
• Inconsistent training: patients with PSS are sometimes missed due 
to insufficient knowledge and a lack of confidence to refer among 
some acute care staff
• Forward planning is limited
• Appointment of a “spasticity champion” on acute wards to connect 
with all teams and train acute care staff on spasticity identification
• Use of risk factors to identify stroke patients at high-risk of 
spasticity
• “Flag” high-risk patients to assure assessment for spasticity at 
patient follow-up
• Development of a standardized pathway for HCPs that can be 
tailored locally to optimize patient management
Low priority • Acceptance of impairment as an inevitable consequence of stroke by 
patients, family and carers
• Low prioritization of PSS management by clinical commissioning 
groups
• Low prioritization of PSS management in primary care
• Long waiting lists for spasticity clinics or outreach visits
• Limited capacity for long-term follow-up of stroke patients
Barriers identified by post-acute care breakout group Potential solutions identified by post-acute care breakout group
High priority* • Poor knowledge among HCPs: insufficient awareness of spasticity 
symptoms and differential diagnoses leads to difficulties in making 
appropriate referrals
• Lack of a standardized process for spasticity assessment
• Limited access: access to specialist services is variable and often 
poor, hindering timely access. Some patients find it difficult to travel 
to secondary care clinics
• Lack of communication/joined-up working between services
• Lack of patient/carer education on spasticity
• Provision of patient information leaflet including checklist that helps 
identify symptoms of PSS
• Pre-discharge conversation with patients/carers to educate patients 
on spasticity
• Spasticity passport carrying individualized patient information
• Greater utilization of existing training resources for HCPs
• Mentoring programmes for allied health professionals 
• Telephone/email triage service to assist community HCPs in making 
appropriate referrals
• Telephone consultations to facilitate regular follow up of patients in 
the community 
• Use of checklists containing risk factors and “indicators for action” 
for HCPs to identify patients requiring further assessment
• Empowering spasticity specialists to visit patients in the community 
in a consulting role
Low priority • Lack of specialist spasticity services in some areas
• Insufficient funding of community rehabilitation services
• Current spasticity services have limited capacity and time for 
inreach and outreach
• Staff managing stroke patients have competing demands, so 
spasticity is not prioritized
• Patients in care homes are missed because of insufficient awareness 
among care home staff caused by high staff rotation
• Patients are not empowered to seek help
• Small numbers of therapists (occupational therapists and 
physiotherapists) working under PGDs 
• Referral processes are sometimes complex, e.g. a requirement 
that referrals come from primary care rather than directly from 
physiotherapists 
High priority* barriers agreed by panel
• Lack of a standardized process for spasticity assessment in stroke patients
• Limited window of opportunity for identification of spasticity in acute care due to a focus on early discharge
• Inconsistent training of stroke staff resulting in lack of confidence in identifying spasticity and referring patients
• Lack of patient education regarding spasticity signs and access to services
• General lack of awareness of spasticity signs, differential diagnoses, treatments available and the benefits of treatment across all community HCPs
• Limited access to spasticity services and expertise in the community
*High-priority barriers are those considered by the panel to have a high impact on patients and to be resolvable in the short term within the current UK healthcare 
framework; all other barriers were considered low priority for the purposes of the consensus process. 
HCP: healthcare professional; PGD: patient group direction; PSS: post-stroke spasticity.
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Key barriers and potential solutions identified by the 
consensus panel
The barriers to timely referral and treatment of patients 
with PSS identified by the acute and post-acute care 
breakout groups are presented in Table II. Key barriers 
(existing throughout the patient journey) prioritized by the 
panel broadly related to lack of awareness and knowledge 
of spasticity, insufficient access to spasticity services and 
a lack of standardized processes/pathways (Fig. 1). Lack 
of awareness of spasticity among HCPs, and particularly 
how to identify it against a background of other muscu-
loskeletal and biomechanical changes, was identified 
as a key barrier at all stages of the patient journey. The 
potential solutions identified by each breakout group to 
address high-priority barriers are also listed in Table II. 
DISCUSSION 
Insufficient awareness of the signs of spasticity among 
some acute care staff means that patients who develop 
signs of spasticity in the acute setting are often discharged 
without a spasticity management plan in place. 
Once discharged into the community, patient access 
to spasticity services and expertise can be limited by 
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Table III. Consensus recommendations to improve timely identification and referral of post-stroke spasticity patients
Implementation setting Recommendation
All settings • Identification of patients with problematic spasticity within routine stroke care settings across the pathway. “Indicators for 
specific specialist spasticity review and possible treatment” have been identified and the corresponding acronym, “ACTION” 
(see Fig. 2), has been developed
Acute care • Appointment of an experienced HCP on the acute ward to act as a “spasticity champion” by liaising with specialist 
rehabilitation teams and taking responsibility for transfer of knowledge and skills to acute care staff
• Identification of patients at high risk of developing spasticity based on the criteria of severe stroke plus 2 or more of the 
following: severe motor weakness, severe sensory loss, communication impairment, unwell with other medical presentations, 
frailty, and neuropathic and/or other pain
• “Flagging” of high-risk patients to stroke and community teams, to facilitate close monitoring of spasticity onset prior to and 
after discharge from hospital
• Patient education (patient awareness and self-management) and their carers on the signs of spasticity, treatments available 
and action to take if they experience symptoms, through a pre-discharge meeting with a member of the acute team and 
provision of patient information 
• Provision of a patient passport containing details of the patient’s stroke, spasticity and any treatment(s)
Community care • Inclusion of “indicators for action” in a pre-clinic screening questionnaire for patients to complete with assistance from an 
HCP (if necessary) prior to follow-up appointments
• Telephone triage services allowing community HCPs to seek advice from specialist spasticity services regarding patients
• Improve access to spasticity expertise by enabling specialist spasticity practitioners to carry out community visits 
• Using existing online training resources to improve knowledge of spasticity among HCPs in the community
Specialist spasticity services • Telephone triage / email services to allow community HCPs to seek advice from specialist spasticity teams regarding patients
• Telephone consultations to improve follow-up of patients in the community who find it difficult to access specialist services 
due to travel difficulties
• Enabling specialist spasticity practitioners normally based in clinics to visit patients in the community (to assess patients and 
review results of treatment)
HCP: healthcare professional; PSS: post-stroke spasticity.
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the highly variable nature of spasticity service 
provision across the UK. Moreover, lack of pa-
tient education on spasticity means that patients 
experiencing spasticity onset following discharge 
are not empowered to seek help. Poor communica-
tion and insufficient integration between primary 
and secondary/tertiary care services in some areas 
further hinders access to spasticity services.
With the aim of improving clinical outcomes and 
quality of life for patients with PSS, we identified 
barriers that hinder the identification and referral of 
patients with PSS in the UK and are surmountable 
in the short term. We propose a set of practical 
recommendations which were agreed following 
extensive discussions and are shown in Table III and 
discussed further below. 
To improve identification and management of PSS at 
all stages of the patient journey, we propose that HCPs 
use a set of “indicators for specific review and possible 
treatment” (Fig. 2). The simple nature of the proposed 
criteria should enable their inclusion in patient informa-
tion leaflets and pre-clinic questionnaires to increase the 
likelihood of timely PSS following discharge. To assist 
HCPs in applying these criteria, we suggest the use of 
the acronym “ACTION” (Fig. 2). 
As spasticity onset occurs more frequently after 
discharge from acute care, all stroke patients should be as-
sessed on the acute ward for their risk of future spasticity 
and high-risk patients should be “flagged” to specialist 
rehabilitation teams for close monitoring after discharge. 
Therefore, we recommend that an experienced member 
of the acute multidisciplinary team (MDT) should liaise 
between the acute, specialist rehabilitation and commu-
nity teams to gain not only increased expertise in PSS 
identification, but also to take responsibility in flagging 
high-risk patients. 
Increased education on spasticity could empower 
patients developing signs of PSS to seek help, while 
a “patient passport” containing details of the patient’s 
stroke and any spasticity (and treatment(s)) could help 
to improve patient management following discharge into 
the community.
The introduction of telephone or email triage services 
would not only facilitate patient follow-up, but would also 
allow community HCPs to seek advice on patients with 
PSS or suspected PSS. These services, together with ena-
blement of specialist spasticity clinic practitioners to visit 
patients in the community, could contribute significantly 
to improving access to specialist spasticity services.
Improving knowledge of spasticity among community 
teams with the use of existing training resources, parti-
cularly easily accessible online resources, should also 
serve to increase access to appropriate care.
Fig. 2. Indicators for specific review and possible treatment of post-stroke 
spasticity (PSS) and associated acronym.
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Limitations of our methodology 
A limitation of this work included the relatively small 
number of respondents chosen for the in-depth interviews 
ahead of the consensus meeting. 
Another limitation consisted in their selection process. 
Although respondents were chosen based on their experti-
se in PSS, further qualifying criteria, such as geographical 
representation or representation of all care settings and 
professional disciplines involved in the management of 
PSS management were not strictly applied (though were 
broadly considered). 
Nonetheless, we hope that this paper will serve as a 
valuable discussion point for stroke services across the 
clinical pathway and that the recommendations we propo-
se will serve as a useful foundation for improving current 
PSS services as well as for the development of formalized 
PSS pathways in areas where none currently exist. 
Future perspectives
While the measures recommended in this paper may not 
all be applicable or implementable in every region, they 
provide a framework for PSS management improvement, 
individual aspects of which could be implemented depen-
ding on the services currently in place and the resources 
available. Some of these recommendations, for example 
telephone consultations, already operate successfully in 
individual centres, but could be rolled out more widely 
and established as standard approach. 
Moreover, the recommendations herein presented could 
potentially be adapted and considered internationally.
In conclusion, we focused on barriers that could be 
realistically addressed in the short-term and on solutions 
that were practical within the current healthcare setting. 
A fundamental barrier that is not easy to address is insuf-
ficient funding, which limits the capacity and resources 
of spasticity services. However, earlier intervention in 
PSS could help to limit the costs associated with post-
stroke management by reducing secondary complications 
and improving long-term outcomes. Cost-effectiveness 
evaluations to demonstrate the long-term benefits of ef-
fective spasticity management will be an important step 
towards the greater prioritization of spasticity treatment 
among commissioners of clinical services and to improve 
the management of PSS on a national scale. 
Monitoring performance in spasticity management 
could increase accountability and provide an incentive 
for greater prioritization of spasticity care. In the UK 
setting, the creation of a national database to support the 
evaluation of performance and outcomes related to PSS 
management would be beneficial to this end. This will, 
however, require time and funding to establish. Inclusion 
of spasticity metrics in the SSNAP could help to drive 
improvements in PSS management. Meanwhile, we 
encourage HCPs to refer to up-to-date Royal College of 
Physicians national clinical guidelines (18) for recom-
mendations to optimize patient management.
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